AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 249 filers reported holding AMICUS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $5,449,000 | -62.5% | 551,478 | -12.3% | 0.00% | -63.6% |
| Q4 2020 | $14,526,000 | +77.2% | 629,106 | +8.4% | 0.01% | +57.1% |
| Q3 2020 | $8,198,000 | +5.3% | 580,563 | +12.4% | 0.01% | -12.5% |
| Q2 2020 | $7,786,000 | +61.5% | 516,331 | -1.0% | 0.01% | +33.3% |
| Q1 2020 | $4,820,000 | -34.1% | 521,600 | -30.5% | 0.01% | -14.3% |
| Q4 2019 | $7,309,000 | +108.0% | 750,362 | +71.3% | 0.01% | +133.3% |
| Q3 2019 | $3,514,000 | +40.6% | 438,112 | +118.7% | 0.00% | 0.0% |
| Q2 2019 | $2,500,000 | -20.1% | 200,300 | -12.9% | 0.00% | -25.0% |
| Q1 2019 | $3,128,000 | +40.0% | 229,998 | -1.4% | 0.00% | +33.3% |
| Q4 2018 | $2,234,000 | -26.9% | 233,198 | -7.7% | 0.00% | -25.0% |
| Q3 2018 | $3,055,000 | -27.2% | 252,698 | -5.9% | 0.00% | -33.3% |
| Q2 2018 | $4,194,000 | +32.3% | 268,498 | +27.4% | 0.01% | +20.0% |
| Q1 2018 | $3,170,000 | -3.2% | 210,771 | -7.4% | 0.01% | +25.0% |
| Q4 2017 | $3,275,000 | +20.0% | 227,570 | +25.7% | 0.00% | 0.0% |
| Q3 2017 | $2,729,000 | +53.3% | 181,000 | +2.4% | 0.00% | +33.3% |
| Q2 2017 | $1,780,000 | +41.2% | 176,800 | 0.0% | 0.00% | +50.0% |
| Q1 2017 | $1,261,000 | +37.5% | 176,800 | -4.2% | 0.00% | 0.0% |
| Q4 2016 | $917,000 | -32.8% | 184,500 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $1,365,000 | -9.7% | 184,500 | -33.3% | 0.00% | 0.0% |
| Q2 2016 | $1,511,000 | -36.0% | 276,800 | -0.9% | 0.00% | -50.0% |
| Q1 2016 | $2,361,000 | -25.4% | 279,400 | -14.3% | 0.00% | -20.0% |
| Q4 2015 | $3,163,000 | -28.1% | 326,100 | +3.7% | 0.01% | -28.6% |
| Q3 2015 | $4,400,000 | -1.1% | 314,500 | 0.0% | 0.01% | 0.0% |
| Q2 2015 | $4,450,000 | +140.7% | 314,500 | +38.5% | 0.01% | +133.3% |
| Q1 2015 | $1,849,000 | 0.0% | 227,100 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $1,849,000 | +167.2% | 227,100 | +95.3% | 0.00% | +200.0% |
| Q3 2014 | $692,000 | +78.4% | 116,300 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $388,000 | +54.0% | 116,300 | 0.0% | 0.00% | – |
| Q1 2014 | $252,000 | +1.2% | 116,300 | 0.0% | 0.00% | – |
| Q4 2013 | $249,000 | -8.5% | 116,300 | -0.8% | 0.00% | -100.0% |
| Q3 2013 | $272,000 | -0.4% | 117,200 | 0.0% | 0.00% | 0.0% |
| Q2 2013 | $273,000 | – | 117,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |